

DirectConnect

Inside Yale Cancer Center

January 27, 2023

Dear Colleagues,

In this issue of DirectConnect, we are announcing several new roles in the Cancer Center all focused on broadening the expertise of our leadership team and preparing for growth in the years ahead. I am immensely grateful to those of you who have agreed to take on additional work and for the added talent these changes bring to our team.

The months ahead are going to be busy. Our Cancer Center Support Grant (CCSG) is due in September, and many of us are hard at work to ensure that we submit the best possible grant to the National Cancer Institute. For those of you who may not be familiar with the CCSG, this is the large grant that supports much of the infrastructure within YCC and is intended to make the entire center far more valuable than if one simply added up the individual components. If individual investigators, labs, and programs are the cellos, violins, and trumpets, the entire cancer center is like a world-famous orchestra – entirely integrated, working together seamlessly, and highly productive.

In addition, we are working to bring even greater alignment to YCC and Smilow than has existed in the past. Yale School of Medicine and Yale New Haven Health are coming closer and closer together in terms of vision, goals, and strategy. YCC and Smilow have long been joined at the hip, but the connection will be even tighter in the months and years ahead. As a result, we are almost certainly going to see further enhancements in patient care, stronger connections between our clinicians and our scientists, and great efficiency in many of our activities.

Finally, we are continuing to work on the full integration of our network sites and the Yale New Haven campus in New Haven. This process is well underway, and it will continue in the months ahead. We look forward to building stronger relationships between the physicians, nurses, administrators, and truly everyone across the system. We all believe this will lead to delivering the best and most consistent care for patients, whenever possible, close to home. The integration will also fuel our clinical trial accrual and our ability to help transform oncology care.

As I near my first anniversary at YCC and Smilow, I am excited about what the future holds. As always, thank you for all that you do. We have a great deal of momentum and will continue to move forward together.

Eric

Eric P. Winer, MD

Director, Yale Cancer Center

Physician-in-Chief, Smilow Cancer Network

Yale
NewHaven
Health
Smilow Cancer
Hospital


Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center



Yale Scientists Enable Massively Parallel

DNA Insertions into Human Cells



[Read More](#)

Usefulness of Podcasts to Provide Public

New Cancer Center Associate and Assistant Directors Named

Yale Cancer Center leadership recently appointed three faculty members to leadership positions for the Center. Please join us in welcoming **Nita Ahuja, MD, MBA**, Chair of Surgery for Yale School of Medicine, Chief of Surgery for Yale New Haven Hospital, and the William H. Carmalt Professor of Surgery, as **Associate Cancer Center Director for Surgical Sciences**. Through this position, Dr. Ahuja will formally share her surgical leadership and expertise as part of Yale Cancer Center's leadership team.



Anne Chiang, MD, PhD, has been named **Associate Cancer Center Director for Clinical Initiatives**. Dr. Chiang joined Yale Cancer Center and Smilow Cancer Hospital in 2011 and has worked with the Smilow leadership team to co-lead the integration of our 15 Care Centers over the last decade. Her experience leading engagement on behalf of the Network will dovetail nicely with her new role within Yale Cancer Center. Dr. Chiang is also an Associate Professor of Medicine (Medical Oncology) and conducts clinical trials in the Center for Thoracic Cancers.



Sanjay Aneja, MD, PhD, has been appointed **Assistant Cancer Center Director for Bioinformatics**. Dr. Aneja's own research investigates the application of machine learning techniques in clinical oncology, including using deep learning to derive biomarkers of cancer

outcomes and clinical trial classification. He completed a research fellowship at the



Usefulness of Podcasts to Provide Public

Education on Prostate Cancer Genetics.

Prostate Cancer and Prostatic Diseases



[Read More](#)

Yale Researchers Develop Software for Individualized Cancer Treatment



[Read More](#)

Older Patients Left Behind in Progress Against Lung Cancer, Yale Study Shows



[Read More](#)

Doctors Seeing Success in HPV Vaccine Against Cancers



Department of Health and Human Services in large scale data analysis and post-doc research in machine learning at the Center for Outcomes Research and Evaluation (CORE) receiving a research grant from IBM Computing. Dr. Aneja will work closely with the new Center for Biomedical Informatics and Data Science in the School of Medicine.



[Read More](#)

Announcements

Pat LoRusso, DO, Nominee for AACR President

Please join us in supporting [Dr. Patricia LoRusso](#), 2024-25 Presidential nominee for the American Association for Cancer Research. We are extremely proud of Pat's nomination and are confident that AACR will benefit greatly from her skilled leadership, dedicated mentorship, and success in translational research.

Pat is the Associate Cancer Center Director for Experimental Therapeutics at Yale Cancer Center and Smilow Cancer Hospital and leader of our Phase I Clinical Trials Program. Throughout her career, her leadership of early phase trials has led to at least 25 agents that subsequently have become FDA approved for the treatment of cancer. Pat's passion for helping patients with cancer is evident in every patient appointment, presentation, meeting, email—it permeates her entire being. This passion will undoubtedly benefit the oncology community nationally as President of AACR.

Please take a moment to learn more about Pat's goals for AACR and share your support today by **submitting your ballot** for the AACR election.

Daniel O'Neil, MD, MPH, joins Smilow Cancer Hospital Care Center in Waterbury

Daniel O'Neil, MD, MPH, has been named an Assistant Clinical Professor of Medicine (Medical Oncology) and will care for patients with breast cancer as part of the




[Presentation at 2023 ASCO Genitourinary Cancers Symposium](#)



[Read More](#)

[Yale's Endocrine Neoplasia Program Is Flourishing](#)



[Read More](#)

Follow us!

facebook



Smilow Cancer Hospital Care Center in Waterbury starting in February. Dr. O'Neil received his medical degree from Albert Einstein College of Medicine and completed residency at Brigham and Women's Hospital in both Internal Medicine and Global Health Equity, and a fellowship at NewYork-Presbyterian/Columbia University Medical Center. He received his MPH with a focus on epidemiology at Harvard T.H. Chan School of Public Health.



Dr. O'Neil's research is focused on understanding the quality of breast cancer care delivered in low- and middle-income countries. He studies the impact of co-morbid HIV on breast cancer outcomes. Women living with both HIV and breast cancer consistently demonstrate higher overall mortality than women living with only breast cancer. Dr. O'Neil's comparisons of breast cancer treatment quality in South African women with and without co-morbid HIV have shown that this disparity in mortality is not primarily driven by differences in cancer care. He is currently working with collaborators in Johannesburg and New Haven, looking for differences in tumor behavior or anti-tumor immune response in women living with HIV.

Precision Medicine Tumor Board

The Precision Medicine Tumor Board provides an opportunity for review and discussion of results from genetic evaluation of tumors performed by the Tumor Profiling Laboratory to facilitate precision oncology care for our patients. Led by **Frederick Wilson, MD, PhD**, and **Zenta Walther, MD, PhD**, patients are discussed **Fridays at 11:30am** with a member of the Tumor Profiling Lab presenting the molecular findings for each patient's tumor and an in-depth scholarly review of the medical literature to provide context to the findings and to identify potentially relevant clinical trials based on the genetic findings. The meetings provide an opportunity for medical oncologists, fellows, and students to interact with members of the Tumor Profiling Lab to interpret results of molecular testing, learn about cancer-related pathways impacted by specific molecular alterations, and to discuss potential treatment opportunities suggested by the findings.

Closer to Free Launch Party

Please join the Closer to Free community on Sunday, March 26 for the official Closer to Free Launch Party! Thank you to Bear's Smokehouse, New Haven for hosting the event as our official launch sponsor.

[Learn More](#)

Notables

Faye Rogers, PhD, Associate Professor of Therapeutic Radiology and Associate Cancer Center Director for Diversity, Equity, and Inclusion, has been appointed to the recently formed **NCCN DEI Directors Forum**.



Meet Annette Hood, PharmD, BCACP, a clinical pharmacist specializing in women's oncology, including breast, ovarian, uterine, and cervical cancers, at Smilow Cancer Hospital. Annette loves being a pharmacist because of the ability to work closely with physicians and nurses on appropriate dosing, administration, and side effect management of medications, but also to talk face-to-face with patients to teach them how to properly take their medications and what to expect from side effects.



Staff Spotlight

Annette Hood, PharmD, BCACP
Clinical pharmacist specializing in Women's Oncology

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Care Program
by the National Cancer Institute

[Read More](#)

Melissa Young, MD, PhD, Associate Clinical

Professor of Therapeutic Radiology, has been appointed Medical Director of the Smilow Cancer Hospital Radiation Oncology Program in New Haven. Dr. Young has provided exemplary leadership to the Trumbull program for the past five years, and we are delighted that she has agreed to take

Michaela Dinan, PhD, Associate Professor of Epidemiology (Chronic Disease) and Co-Leader of Yale Cancer Center's Cancer Prevention and Control Program, has been named **Associate Editor of the *Journal of the National Cancer Institute (JNCI)***.

Jill Lacy, MD, Professor of Medicine (Medical Oncology), has been appointed **Editor-in Chief of ASCO-SEP**, the medical oncology self-evaluation program.

Luisa F. Escobar-Hoyos, PhD, Assistant Professor of Therapeutic Radiology, and **Mandar Muzumdar, MD**, Assistant Professor of Genetics and Medicine (Medical Oncology), have both received Stage 2 continuation support for Innovator Awards from the Damon Runyon Cancer Research Foundation to fund their projects. Dr. Escobar-Hoyos is studying, "Understanding RNA splicing in tumor-cell adaptation and anti-tumor immunity," and Dr. Muzumdar is researching, "Targeting endocrine-exocrine signaling in pancreatic ductal adenocarcinoma progression."

Christina Matousek, MSN, RN, OCN, NPDS, has been appointed to a new role in the Nursing Education and Practice department serving as **Fellowship Specialist** and is overseeing the Smilow New Graduate Ambulatory Oncology RN and APP Fellowship. The Smilow New Graduate Ambulatory Oncology RN and APP Fellowship is a new program that is graciously funded by the Frederick A. DeLuca Foundation.

Brooke Schrameck, MSN, RN, has been promoted to **Clinical Program Manager** of the Smilow Cancer Hospital Care Centers in Derby, Torrington, and Waterbury. Brooke joined the Smilow Cancer Hospital Care Center team in 2018. She was the recipient of a Smilow Shares Scholarship Award in 2021 and was selected for and graduated from the YNH New Nurse Manager Residency Program in 2022.

Laura J. Morrison, MD, FAAHPM, Associate Professor of Medicine and Director of the Yale Hospice and Palliative Medicine Fellowship Program, has been elected to a second 3-year term as **Physician Director-At-Large** on the **Board of Directors for the American Academy of Hospice and Palliative Medicine (AAHPM)**. This next term will begin March 24, 2023 at the AAHPM/Hospice and Palliative Nurses Association Annual Assembly held in Montreal.

Vanessa Suarez recently joined the Director's Office at Yale Cancer Center as a **Senior Administrative Assistant**, assuming administrative support responsibilities for Eric Winer, MD. Vanessa has over a decade of experience in executive leadership support, project management, and communications.

The **Cancer Immunology Research Program** welcomes **John Tsang**,

PhD, Professor of Immunobiology and Biomedical Engineering and founding Director of the Yale Center for Systems and Engineering Immunology (CSEI). The CSEI serves as a cross-departmental home, enabler, and center of collaboration for systems,




we are delighted that she has agreed to take on this new role in New Haven.



[Read More](#)

Cervical Cancer Awareness Month is recognized throughout the month of January. It is a common cancer for women between the ages of 35-44 and as Dr. Shari Damast, Professor of Therapeutic Radiology and Chief of the Gynecologic Radiotherapy Program, shares, screening is a critical component to preventing this cancer.

"Cervical Cancer is most commonly diagnosed in women ages 35-44, with the highest incidences in Hispanic, Black, and Native American populations. In more than 95% of cases, Human Papillomavirus (HPV) is central to the development of Cervical Cancer. Screenings—pap smears and HPV testing, has led to a decrease in cervical cancer mortality, and has improved early and asymptomatic detection."



[Read More](#)

The Cancer Immunology Research Program welcomes Alexa Siddon, MD, Associate Professor of Laboratory Medicine and Pathology. Dr. Siddon is a

quantitative, and synthetic immunology at Yale, including cancer immunology. Dr. Tsang's lab combines both computational and experimental approaches, including multimodal immune profiling, data science, machine learning, quantitative dynamical modeling, and ex vivo experiments and animal models, to investigate the basis of human immune response variability.



DEI Update

Workshop for Women Faculty on Building Your Career Infrastructure

The Office for Women in Medicine and Science will present an in-person workshop on executive presence and building your career infrastructure on Friday, February 17, 2023 from 9:00am -12:30pm.

The workshop is geared toward YSM women faculty at all career stages. Your presence will increase women's visibility with senior leaders and potentially facilitate opportunities for senior leaders to sponsor women—to help develop women leaders by providing advice, guidance and feedback; advocating for promotions or other opportunities; and encouraging and supporting women to take risks.

[Learn More](#)

A Conversation on LGBTQI+ Health & Gender-Affirming Care

Please join the Solomon Center for Health Law and Policy on Monday, February 6 at 12:10pm for a discussion with Admiral Rachel Levine, MD, the Assistant Secretary for Health at the U.S. Department of Health and Human Services. Admiral Levine will discuss legal and societal barriers to gender-affirming care, including the role physicians play in advocacy and addressing misinformation.

[Learn More](#)

Employee Profile: Jenna Addison, DNP, FNP-BC, CBCN

Jenna Addison, DNP, has been caring for women with breast cancer at the Smilow Cancer Hospital Care Center in Trumbull and at Bridgeport Hospital for more than six years. Since nursing school, she knew she wanted to pursue women's health in some capacity. After working at Yale New Haven Hospital and Bridgeport Hospital as an RN, she stayed in Bridgeport once completing APRN training and has happily been there ever



hematopathologist, diagnosing numerous malignant hematolymphoid neoplasms. Dr. Siddon has several diverse research interests within the field of hematopathology. Her overall focus is on malignant hematopathology, as well as immunohematology and coagulation. Further, she is interested in the overlap between hematology and transfusion support for patients.



WELCOME

Alexa Siddon, MD


Associate Professor of Laboratory Medicine and Pathology

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)

Recently on Yale Cancer Answers, palliative care specialist Dr. Andrew Putnam discussed pain and symptom management in people with severe disease including cancer, and the importance of physician-patient communication. Listen on Connecticut Public Radio or download our podcast from iTunes.



YALE CANCER ANSWERS

Pain and Symptom Management for Cancer Patients

Andrew Putnam, MD
Assistant Professor, Clinical Medicine (General Medicine); Assistant Clinical Professor, Nursing

Sunday, January 22 at 7:30pm
Listen live on WNPR or stream via ctpublic.org
Download our podcast on iTunes

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)

Our team at the Smilow Cancer Hospital Care Center at Greenwich Hospital joined together to generously donate gift cards to help make the holiday season a little brighter for one of their patients and her family. Thank you to the entire team for your caring spirit!



since.

Three days a week, Jenna is in the clinic seeing patients, and is in a shared practice with Dr. Melanie Lynch twice a week. She also supports Dr. Mehra Golshan & Dr. Monica Valero's patients. She meets with new patients and patients in long-term cancer survivorship, conducts pre- and post-operative follow-up, and supports patients who have benign conditions and concerns.



Gean Brown, MSN, RN, OCN, CNML, Clinical Program Manager, Breast Center and Surgical Oncology, Smilow Cancer Hospital Care Center in Trumbull, says, "The knowledge Jenna has for breast diagnoses and her quality compassionate care of our patients, is truly exemplary."

"I love seeing my regular patients and seeing them reach milestones," says Jenna. "We have several patients who are celebrating 25-plus years of survivorship, and those experiences are especially meaningful."

Jenna notes how improvements in breast imaging, such as 3D mammography has really made big strides, helping improve early detection, decreasing imaging callbacks, and has contributed to survivorship longevity, helping detect subtle findings.

"Jenna has been a stabilizing force in the Smilow Cancer Hospital breast centers in Trumbull, Fairfield, and Bridgeport," shared Lisa Shomsky, MBA, BSN, CNML, Regional Director, Smilow Network. "She can cover in any of our three locations during physician absences and is the person staff rely on for guidance regarding patient care."

Recent Publications

Rodler, E., Sharma, P., Barlow, W. E., Gralow, J. R., Puhalla, S. L., Anders, C. K., Goldstein, L., Tripathy, D., Brown-Glaberman, U. A., Huynh, T. T., Szyarto, C. S., Godwin, A. K., Pathak, H. B., Swisher, E. M., Radke, M. R., Timms, K. M., Lew, D. L., Miao, J., Pusztai, L., Hayes, D. F., Hortobagyi, G.N. **Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.** *The Lancet. Oncology*, S1470-2045(22)00739-2.

[Read More](#)

Speers, C. W., Symmans, W. F., Barlow, W. E., Trevarton, A., The, S., Du, L., Rae, J. M., Shak, S., Baehner, R., Sharma, P., Pusztai, L., Hortobagyi, G. N., Hayes, D. F., Albain, K. S., Godwin, A., & Thompson, A.

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2201499.

[Read More](#)

Lambertini, M., Ceppi, M., Anderson, R. A., Cameron, D. A., Bruzzone, M., Franzoi, M. A., Massarotti, C., El-Abed, S., Wang, Y., Lecocq, C., Nuciforo, P., Rolyance, R., Pusztai, L., Sohn, J., Latocca, M. M., Arecco, L., Pistilli, B., Ruddy, K. J., Ballestrero, A., Del Mastro, L., Demeestere, I.

Impact of Anti-HER2 Therapy Alone and With Weekly Doxorubicin on the



[Read More](#)

Congratulations to Patrick A. Kenney, MD, who was recently appointed Service Line Medical Director for Greenwich Hospital and Regional Physician Leader for Oncology Growth. Dr. Kenney's clinical leadership at the Yale New Haven Health System and dedication on behalf of our physicians, nurses, caregivers, and our patients has led to streamlined patient care and innovations in healthcare delivery. In his new role as medical director, Dr. Kenney will continue to build multidisciplinary cancer care and further develop integrated clinical programs at the Smilow Cancer Hospital Care Center in Greenwich. In addition, he will serve as the primary ambassador for our Center in Greenwich, representing Greenwich Hospital, Yale Cancer Center, and Smilow Cancer Hospital in the region, ultimately growing our practice.

An Associate Professor of Urology at Yale School of Medicine, Dr. Kenney specializes in treating genitourinary cancers, with a particular focus on kidney cancers. He performs robotic, laparoscopic, and open surgery for kidney cancer, with an emphasis on organ and function preservation and minimally invasive surgery whenever feasible. Dr. Kenney's research interests are in the integration of surgery and systemic therapy for locally advanced, metastatic, and treatment-resistant kidney cancer.



Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 21(1), 33–41.e16.

[Read More](#)

Nanou, A., Miao, J., Coumans, F. A. W., Dolce, E. M., Darga, E., Barlow, W., Smerage, J. B., Paoletti, C., Godwin, A. K., Pusztai, L., Sharma, P., Thompson, A., Hortobagyi, G. N., Terstappen, L. W. M. M., & Hayes, D. F.
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer.
JCO precision oncology, 7, e2200372.

[Read More](#)

Bhatia, A., & Burtness, B.
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Drugs, 10.1007/s40265-023-01835-2.

[Read More](#)

Marczyk, M., Fu, C., Lau, R., Du, L., Trevarton, A. J., Sinn, B. V., Gould, R. E., Pusztai, L., Hatzis, C., & Symmans, W. F.
Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.
Cancer cytopathology, 10.1002/cncy.22679.

[Read More](#)

Marczyk, M., Fu, C., Lau, R., Du, L., Trevarton, A. J., Sinn, B. V., Gould, R. E., Pusztai, L., Hatzis, C., & Symmans, W. F.
Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.
Cancer cytopathology, 10.1002/cncy.22679.

[Read More](#)

Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karipott, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., Saeed, A., Rajdev, L.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2202331.

[Read More](#)

Farrell, J. J., Robert, M. E., & Lacy, J.
Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, S1542-3565(23)00036-8.

[Read More](#)

Dizman, N., Austin, M., Considine, B., Jessel, S., Schoenfeld, D., Merl, M. Y., Hurwitz, M., Sznol, M., & Kluger, H.
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Clinical genitourinary cancer, S1558-7673(23)00002-2.

[Read More](#)

Pan, Y. E., Hood, A., Ahmad, H., & Altwerger, G.
Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
The Annals of pharmacotherapy, 10600280221149136.

[Read More](#)

Rory Michael Shallis, Julian Weiss, Eric S. Winer, Talha Badar, Alok

Patrick A. Kenney, MD

Appointed Service Line
Medical Director for
Greenwich Hospital
and Regional Physician
Leader for Oncology
Growth



YaleNewHavenHealth
Smilow Cancer Hospital

Yale
CANCER
CENTER
A Comprehensive Cancer Care Organization
by the National Cancer Institute

[Read More](#)



A study led by Dr. Veda Giri @vedangiri shows how #podcasts are a useful, easy-to-understand tool to awareness & provide education on #prostatecancer genetic evaluation.



Thank you to Dr. Lisa Newman @WeillCornell for an insightful @YaleCancer Grand Rounds on #breastcancerdisparities and how African Ancestry can predispose women to #TNBC.



“Using (the) #HPV vaccine is so effective in not just preventing #cancer, but also preventing pre-cancer and everything else associated with it,” said Dr. Elena Ratner in an interview with @WTNH.



Research led by Drs. Melinda Irwin @mirwin_yale & Leah Ferucci on the impact of #exercise on #QOL in #ovariancancer survivors found that women who attended more counseling sessions were more likely to meet their goals.



Research from Dr. Tamar Taddei shows recent advances in the understanding of systemic therapies for hepatocellular carcinoma #HCC could expand the pool of patients potentially benefitting from surveillance.



Today at 12pm, Dr. Lisa Newman, Chief of Breast Surgery at Weill Cornell Medicine @WeillCornell, will present “Oncologic Anthropology: African Ancestry and #TNBC” at #GrandRounds. Join us in person or via Zoom.



Dr. Melissa Young @RasarYoungMDPhD has been appointed Medical Director of the Smilow Cancer Hospital Radiation Oncology

Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Annie Im, Yasmin Abaza, Mark R. Litzow, Nikolai A. Podoltsev
Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Blood (2022) 140 (Supplement 1): 8921–8922.
[Read More](#)

Loeb, S., Sanchez Nolasco, T., Siu, K., Byrne, N., & Giri, V. N.
Usefulness of podcasts to provide public education on prostate cancer genetics.
Prostate cancer and prostatic diseases, 10.1038/s41391-023-00648-4.
[Read More](#)

Shepherd, J. H., Ballman, K., Polley, M. C., Campbell, J. D., Fan, C., Selitsky, S., Fernandez-Martinez, A., Parker, J. S., Hoadley, K. A., Hu, Z., Li, Y., Soloway, M. G., Spears, P. A., Singh, B., Tolaney, S. M., Somlo, G., Port, E. R., Ma, C., Kuzma, C., Mamounas, E., Sikov, W. M.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(12), 1323–1334.
[Read More](#)

Lozano, A. X., Chaudhuri, A. A., Nene, A., Bacchiocchi, A., Earland, N., Vesely, M. D., Usmani, A., Turner, B. E., Steen, C. B., Luca, B. A., Badri, T., Gulati, G. S., Vahid, M. R., Khameneh, F., Harris, P. K., Chen, D. Y., Dhodapkar, K., Sznol, M., Halaban, R., & Newman, A. M.
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Nature medicine, 28(2), 353–362.
[Read More](#)

Gavrielatou, N., Liu, Y., Vathiotis, I., Zugazagoitia, J., Aung, T. N., Shafi, S., Fernandez, A., Schalper, K., Psyrris, A., & Rimm, D. L.
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(2), 360–367.
[Read More](#)

Lokeshwar, S. D., Syed, J. S., Segal, D., Rahman, S. N., & Sprengle, P. C.
Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer.
Current oncology reports, 24(2), 249–256.
[Read More](#)

Garcia-Manero, G., Mufti, G. J., Fenaux, P., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Ilhan, O., Sekeres, M. A., Zeidan, A. M., Ito, R., Zhang, J., Rampersad, A., Sinsimer, D., Backstrom, J. T., Platzbecker, U., & Komrokji, R. S.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood, 139(4), 624–629.
[Read More](#)

Murthy, H. S., Ahn, K. W., Estrada-Merly, N., Alkhateeb, H. B., Bal, S., Kharfan-Dabaja, M. A., Dholaria, B., Foss, F., Gowda, L., Jagadeesh, D., Sauter, C., Abid, M. B., Aljurf, M., Awan, F. T., Bacher, U., Badawy, S. M., Battiwalla, M., Bredeson, C., Cerny, J., Chhabra, S., Saber, W.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Transplantation and cellular therapy, 28(4), 187.e1–187.e10.
[Read More](#)

Program in New Haven. Congratulations, Dr. Young!

 A study from Drs. Gloria Huang @GloriaHuangMD and Alessandro Santin reports adjuvant therapy following surgery is critical for women who have early and advanced stage #endometrialcancer.

 Tonight at 7:30pm on Yale Cancer Answers, #palliativecare specialist Dr. Andrew Putnam discusses pain & symptom management in people with severe disease including #cancer, and the importance of physician-patient communication. Listen live on @wnpr.

 Brachytherapy is a vital component for the curative treatment of #cervicalcancer. This study explores the importance of #sexualhealth and #QOL in patients, & how intervention can prevent + treat vaginal and sexual symptoms.

 A @JCO_ASCO Oncology Grand Rounds case scenario led by Dr. Meena Moran and co-author Dr. Alice Ho reviews radiation therapy options for a 66 y/o female with #breastcancer.

 Dr. Barbara Burtness and @AartiBhatiaMD share "Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update"

 A study published in @oncologynursing explores year one of the #COVID19 pandemic and its impact on oncology nurses at Smilow Cancer

Hospital.

 Aarti Bhatia, MD, MPH, @AartiBhatiaMD Associate Professor of Medicine (Medical Oncology), has been named Leader of the Head & Neck Disease-Aligned Research Team. Congratulations!

Calendar

Yale Cancer Answers: Global Health and Oncology

Read More

Sepich-Poore, C., Zheng, Z., Schmitt, E., Wen, K., Zhang, Z. S., Cui, X. L., Dai, Q., Zhu, A. C., Zhang, L., Sanchez Castillo, A., Tan, H., Peng, J., Zhuang, X., He, C., & Nachtergaele, S.

The METTL5-TRMT112 N6-methyladenosine methyltransferase complex regulates mRNA translation via 18S rRNA methylation.

The Journal of biological chemistry, 298(3), 101590.

Read More

Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., Terrell, D. R., Schünemann, H. J.

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.

Blood advances, 6(2), 664–671.

Read More

Bewersdorf, J. P., & Zeidan, A. M.

Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?

Expert review of anticancer therapy, 22(3), 239–241.

Read More

Liu, F., Peng, B., Li, M., Ma, J., Deng, G., Zhang, S., Sheu, W. C., Zou, P., Wu, H., Liu, J., Chen, A. T., Mohammed, F. S., & Zhou, J.

Targeted disruption of tumor vasculature via polyphenol nanoparticles to improve brain cancer treatment. Cell reports.

Physical science, 3(1), 100691.

Read More

Billingsley K. G.

The Next Step in Tumor Board Evolution: Optimizing Care Coordination and Integration : Editorial on "Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies".

Annals of surgical oncology, 29(4), 2146–2147.

Read More

Sun, T. Y., Hwang, G., Pancirer, D., Hornbacker, K., Codima, A., Lui, N. S., Raj, R., Kunz, P., & Padda, S. K.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour.

The European respiratory journal, 59(1), 2101058.

Read More

Foggetti, G., Li, C., Cai, H., Petrov, D. A., Winslow, M. M., & Politi, K.

Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment.

Molecular & cellular oncology, 9(1), 1994328.

Read More

Al-Lamki, R. S., Wang, J., Pober, J. S., & Bradley, J. R.

Co-Expression and Functional Interactions of Death Receptor 3 and E-Selectin in Clear Cell Renal Cell Carcinoma.

The American journal of pathology, 192(4), 722–736.

Read More

Yang, Y., Sun, Q., Huang, L., Broome, J. G., Correa, A., Reiner, A., NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Raffield, L. M., Yang, Y., & Li, Y.

eSCAN: scan regulatory regions for aggregate association testing using whole-genome sequencing data.

Briefings in bioinformatics, 23(1), bbab497.

January 29; 7:30 PM

Donna Spiegelman, ScD

Learn More

Yale Cancer Center Grand Rounds

January 31; 12:00 PM

55 Park Street; Auditorium

Hepatocellular Carcinoma – From Screening to Treatment: Current Practice, Pearls, and Puzzles

Tamar Taddei, MD

Learn More

Immunobiology Seminar Series

February 2; 10:30 AM

The Anlyan Center; Auditorium, N-107

Dissecting The Role of Lymphatic Transport In Cutaneous Immune Surveillance: From Infection To Malignancy

Amanda Lund, PhD

Read More

Pharmacology Seminar Series presents

February 2; 12:30 PM

Brady Memorial Laboratory

The Meshcode Theory – Does Our Brain Store Memories in Binary Format?

Ben Goult

Learn More

Cancer Genetics and Prevention Program Seminar

February 2; 2:30 PM

Learn More

Center for GI Cancers /Yale Pancreatic Cancer Collaborative Seminar

February 2; 4:15 PM

Gary Désir, MD

Learn More

Program for Humanities in Medicine seminar

February 2; 5:00 PM

The Anlyan Center; N107, 1

Language for an Infinite Distance: Art as Work in Medicine

Anna DeForest, MD, MFA

Learn More

Surgery Grand Rounds

February 3; 7:30 AM

Fitkin Memorial Pavilion Auditorium

Nita Ahuja, MD, MBA, FACS | Karen E.

Gibbs, FACS, FASMBS, MD | Melissa

Read More

Leitner, B. P., Givechian, K. B., Ospanova, S., Beisenbayeva, A., Politi, K., & Perry, R. J.

Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma.

NPJ precision oncology, 6(1), 8.

Read More

Bewersdorf, J. P., Prozora, S., Podoltsev, N. A., Shallis, R. M., Huntington, S. F., Neparidze, N., Wang, R., Zeidan, A. M., & Davidoff, A. J.

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.

Blood advances, 6(2), 376–385.

Read More

Liu, M., Zou, X., Chen, J., & Ma, S.

Comparative Analysis of Social Support in Online Health Communities Using a Word Co-Occurrence Network Analysis Approach.

Entropy (Basel, Switzerland), 24(2), 174.

Read More

Hung, F., Hofmann, J. N., Josse, P. R., Locke, S. J., Stapleton, E. M., Andreotti, G., Deziel, N. C., Beane Freeman, L. E., & Friesen, M. C.

Observed vs. self-reported agricultural activities: Evaluating 24-hr recall in a pilot study.

Journal of occupational and environmental hygiene, 19(2), 87–90.

Read More

Naraparaju, V., Mosleh, W., Almnajam, M., Khaddr, M., Bagade, S., Posteraro, A., Grew, D., Wakefield, D. B., Hur, D. J., & Vashist, A.

The utility of radiographic assessment of the internal mammary arteries in chest wall irradiated patients.

Frontiers in bioscience (Landmark edition), 27(1), 30.

Read More

Zeidan, A. M., Cook, R. J., Bordoni, R., Berenson, J. R., Edenfield, W. J., Mohan, S., Zhou, G., Asatiani, E., Srinivas, N., & Savona, M. R.

A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.

Clinical lymphoma, myeloma & leukemia, 22(7), 523–534.

Read More

Lerner, B. A., Xicola, R. M., Rodriguez, N. J., Karam, R., & Llor, X.

Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants.

Journal of medical genetics, 60(1), 36–40.

Read More

Ribrag, V., Chavez, J. C., Boccomini, C., Kaplan, J., Chandler, J. C., Santoro, A., Corradini, P., Flinn, I. W., Advani, R., Cassier, P. A., Sangha, R., Kenkre, V. P., Isufi, I., Uttamsingh, S., Hagner, P. R., Gandhi, A. K., Shen, F., Michelliza, S., Haeske, H., Hege, K., Kuruvilla, J.

Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

EJHaem, 3(1), 139–153.

Read More

Savard, M. F., Kornaga, E. N., Kahn, A. M., & Lupichuk, S.

Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status.

Current oncology (Toronto, Ont.), 29(1), 383–391.

Read More

Perkal, MD | Ronnie Rosenthal, MD |

Barbara A. Ward, MD

Learn More

Yale Cancer Answers

February 5; 7:30 PM

Caring for a Pregnant Patient with Cancer
Mariya Rozenblit, MD | Katherine Kraschel, JD

Learn More

Yale Cancer Center Grand Rounds

February 7; 12:00 PM

55 Park Street; Auditorium

Radiofrequency Ablation Of Thyroid Nodules: Current Indications And Future Considerations

Courtney Elizabeth Gibson, MD, MS, FACS

Learn More

Yale Cell Biology Seminar Series

February 7; 1:00 PM

The Anlyan Center; TAC N107, 1

Activation of the Exocyst Tethering Complex for SNARE Complex Regulation and Membrane Fusion

Mary Munson, PhD

Learn More

Smilow Shares with Primary Care on Gynecologic Oncology

February 7; 5:00 PM

Johanna D'Addario, MHS, PA-C | Mitchell Clark, MD | Jeffrey Josephs, MD | Christi Kim, MD, FACP

Learn More

Cancer Biology Meeting (Hybrid)

February 8; 4:00 PM

Brady Memorial Laboratory; 137

Learn More

Yale Cancer Center Cancer Biology Meeting

February 8; 4:00 PM

Anupama Hemalatha | Sara Gallini

Learn More

Dean's Workshop

February 9; 1:00 PM

The Anlyan Center; N-107

Human Organoids and Stem Cells as Experimental Models...

Nancy J. Brown, MD | Flora Vaccarino, MD |

Haifan Lin, PhD | Berna Sozen, PhD |

Anjelica Gonzalez, PhD | Andre Levchenko |

Watane, A., Hansen, E. D., Vazquez, L. E., & Karp, C. L.

Ocular Surface Squamous Neoplasia Masquerading as Recalcitrant Epithelial Keratitis.

Cornea, 41(9), 1185–1187.

[Read More](#)

Kang, D. W., Wilson, R. L., Christopher, C. N., Normann, A. J., Barnes, O., Lesansee, J. D., Choi, G., & Dieli-Conwright, C. M.

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity.

Frontiers in cardiovascular medicine, 8, 805735.

[Read More](#)

Charles J. Robbins, Aileen I. Fernandez, Gang Han, Serena Wong, Malini Harigopal, Mirna Podoll, Kamaljeet Singh, Amy Ly, M. Gabriela Kuba, Hannah Wen, Mary Ann Sanders, Jane Brock, Shi Wei, Oluwole Fadare, Krisztina Hanley, Julie Jorns, Olivia L. Snir, Esther Yoon, Kim Rabe, T. Rinda Soong, Emily S. Reisenbichler, David L. Rimm,

Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.

Modern Pathology, Volume 36, Issue 1, 2023, 100032, ISSN 0893-3952.

[Read More](#)

Funding and Award Opportunities

Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01)

The purpose of this FOA is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.

Application Deadline: February 5, 2023

[Read More](#)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01)

This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs)

and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups are encouraged to work with their institutions to apply.

Application Deadline: February 6, 2023

[Read More](#)

Transformative Educational Advancement and Mentoring Network (TEAM) (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

Application Deadline: February 10, 2023

[Read More](#)

2023 K12 Immuno-Oncology Training Program (IOTP) Scholar Award

YCC-IOTP Scholar Award is an award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training. Successful applicants are required to demonstrate a strong commitment to a career in cancer immunology. The two-year IOTP curriculum includes didactic and practical training in basic, translational and clinical aspects of cancer

In-Hyun Park, PhD | Yong-Hui Jiang, MD,

PhD | Alexej Abyzov

[Learn More](#)

Cancer Genetics and Prevention Program Seminar

February 9; 2:30 PM

[Learn More](#)

C&M Physiology Seminar

February 9; 4:00 PM

Sterling Hall of Medicine, B-Wing; Giarman Room, 2nd Floor

Altered Lipid Metabolism in Pancreatic Cancer Cachexia

Aaron Grossberg, M.D., Ph.D.

[Learn More](#)

Center for GI Cancers Journal Club

February 9; 4:15 PM

Man Yee Merl, PharmD

[Learn More](#)

Endocrinology Clinical Dilemma

February 10; 12:00 PM

Boyer Center for Molecular Medicine; 206/208

Oyunbileg Magvanjav

[Learn More](#)



Share your news!

Please submit your recent publications, awards, and grant announcements to:

[Renee Gaudette](#)

Director, Public Affairs and Communications

immunology research. The program also includes a required research component (either clinical or bench research, or a combination thereof). Applicants are required to identify a mentor and provide a research and mentorship proposal.

Full Application Due: February 15, 2023

Read More

Gabrielle's Angel Foundation – Mark Foundation Collaborative Grant Award

Gabrielle's Angel Foundation and The Mark Foundation for Cancer Research announce the development of a collaborative research program involving investigators currently or previously funded by Gabrielle's Angel Foundation. This award presents those proven and accomplished researchers with the opportunity to explore new ideas together in a collaborative setting.

Letters of Intent Due: February 17, 2023

Read More

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01)

The purpose of this FOA is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.

Application Deadline: February 21, 2023

Read More

ALSF 2023 POST (Pediatric Oncology Student Training) Program

The POST Program provides an opportunity for students to train with a mentor who is conducting research in the field of pediatric oncology. The POST Program is designed for undergraduate, graduate and medical students interested in pursuing a career in pediatric oncology research. PhD students are not eligible to apply.

Application Deadline: February 21, 2023

Read More

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00)

The purpose of this FOA is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.

Application Deadline: February 21, 2023

Read More

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025

This FOA supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Application Deadline: February 22, 2023

Read More

AACR Clinical Oncology Research (CORE) Training Fellowships

The AACR Clinical Oncology Research (CORE) Training Fellowships Program is designed to provide an industry-academic clinical practicum with a unique opportunity for academic clinicians to train in drug development. Each fellowship provides \$100,000 over one year for the fellow to work on site at the facility of one of the AACR's pharmaceutical industry partners.

Application Deadline: February 23, 2023

Read More

NCI Cancer Screening Research Network Funding Opportunities

The CSRN conducts rigorous, multi-center cancer screening trials and studies with large and diverse populations in a variety of health care settings with the goal of reducing cancer incidence and cancer-related morbidity and mortality. Cancer screening provides a unique opportunity to diagnose cancers and pre-cancerous lesions before symptoms develop.

- **ACCruaI, Enrollment, and Screening Sites (ACCESS) Hub (UG1)**

Read More

- **Statistics and Data Management Center (UG1)**

Read More

- **Coordinating and Communication Center (UG1)**

Read More

Application Deadlines: February 28, 2023

Yale Chapter of the National Bouchet Graduate Honor Society

The Yale Chapter of the National Bouchet Graduate Honor Society is currently accepting nominations for graduate student, postdoc, and faculty membership for induction on March 31, 2023 as part of the annual Yale Bouchet Conference on Diversity and Graduate Education.

Application Deadline: March 1, 2023

Read More

BRCA Research & Cure Alliance

The BRCA Research & Cure Alliance (CureBRCA) will consider funding BRCA-related initiatives that involve prevention, detection, screening, and/or treatment for men at risk for BRCA-related cancers. Applications will be evaluated by CureBRCA leadership, the CureBRCA Scientific Advisory Committee, and if appropriate: patients, carriers, and/or genetic counselors.

Application Deadline: March 1, 2023

Read More

JH Milstone Fund Grant

JH Milstone Fund will award a grant in 2023 to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important. For more information, please contact **Richard**

Carr.

Letter of Intent Due: March 1, 2023

Read More

CRI Immuno-Informatics Postdoctoral Fellowship

The CRI Immuno-Informatics Postdoctoral Fellowship Program aims to support qualified young scientists at academic research institutions around the world who wish to receive dual training in immunology and data science. The fellowships will support both computational biologists who seek to strengthen their knowledge of immunology and cancer immunologists who seek training in computational biology, data science, and/or genomics under the mentorship of world-renowned scientists in these disciplines.

Applications Deadline: March 1, 2023

Read More

NIH Enhancing the Use of the All of Us Research Programs Data (R21)

The *All of Us* Research Program within the Office of the Director (OD) encourages investigators to apply for grant awards that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the *All of Us* Research Program's Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community.

Application Deadline: March 1, 2023

Read More

NIH Small Grants to Enhance the Use of the All of Us Research Programs Data (R03)

The *All of Us* Research Program within the Office of the Director (OD) encourages investigators to apply for grant awards that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the *All of Us* Research Program's Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community.

Applications Deadline: March 1, 2023

Read More

DeLuca Career Development Award

The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the goal to achieve independent support for their research from a national agency. For more information, please contact **Richard Carr**.

Letter of Intent Due: March 1, 2023

Read More

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Application Deadline: March 1, 2023

Read More

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This FOA invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

Application Deadline: March 1, 2023

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Deadline: March 1, 2023

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Application Deadline: March 1, 2023

Read More

YCCI Educational Funding Support Opportunities

- **YCCI Multidisciplinary Post-Doctoral Training Program in Translational Research:** provide an opportunity for Yale post-doctoral trainees in the Schools of Medicine, Nursing, Public Health, Engineering and Applied Science or other appropriate Departments in the Graduate School to receive up to 2 years devoted to training across the full span of clinical and translational research focused on human health.

Application Deadline: March 10, 2023

Read More

- **YCCI Multidisciplinary Pre-Doctoral Training Program in Translational Research:** aims to identify and support a representative and diverse group of outstanding trainees who specifically want to pursue careers in clinical and translational research; to train them in the use of state-of-the-art research tools; to enhance their abilities to work collaboratively in complex multidisciplinary research teams; to provide outstanding mentoring (including concordant mentoring) by experienced and diverse faculty that support the trainee's long-term professional development.

Application Deadline: March 10, 2023

Read More

NY Academy of Sciences: Innovators in Science Award: CANCER IMMUNOLOGY

The 2024 Innovators in Science Award will recognize achievements in Cancer Immunology. We welcome nominations from government, non-profit, or equivalent institutions around the world, as well as from the Award's own Scientific Advisory Council, composed of renowned science and technology

leaders. Prize winners will be chosen by a panel of judges independently selected by the New York Academy of Sciences, and the Awards will be conferred at a ceremony in early 2024.

Internal Submission Deadline: March 13, 2023

Read More

AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01)

The goal of this FOA is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This initiative will encourage development, evaluation, and validation of biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early HNC.

Application Deadline: March 14, 2023

Read More

Diversity and Inclusion in Breast Cancer Research

The following research awards are designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. These awards are made possible through the support of the Breast Cancer Research Foundation (BCRF).

- **Career Development Award:** Full Application Due: March 13, 2023

Read More

- **Young Investigator Award:** Full Application Due: March 13, 2023

Read More

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03)

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of

childhood cancers and/or structural birth defects.

Application Deadline: March 16, 2023

Read More

The Chênevert Family Brain Tumor Center at Yale Developmental Research Awards

The Chênevert Family Brain Tumor Center at Yale is pleased to announce DEVELOPMENTAL RESEARCH AWARDS with first funding beginning 07/01/2023 to projects in amounts up to \$100,000 over two years.

The projects must focus on primary or metastatic brain tumors, and they must have a translational focus or high potential to lead to a translational project or a clinical trial.

Internal Submission Deadline: March 31, 2023

Read More

ACS Research Priority Area: Screening

Detecting cancer early saves lives. Unfortunately, the important benefits of cancer screening are not reaching enough people. The purpose of this RFA is to fund innovative research that will facilitate more widespread cancer screening and early detection culminating in reduced cancer mortality.

Internal Submission Deadline: April 3, 2023

Read More

HESI THRIVE Grant

A proud partner of the **Biden Cancer Initiative**, THRIVE provides seed grants for clinical and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.

Letters of Intent Due: April 10, 2023

Read More

Joint SPORE Developmental Research Program (DRP) Award – Cancer

Disparities

The YCC Translational Research Office in collaboration with the Yale SPORE in Lung Cancer (YSILC) and the Yale Head and Neck SPORE (YHN-SPORE) have launched a new DRP award to provide support up to \$50,000 for a translational pilot project focused on **disparities-related cancer research** in the field of Head and Neck and/or Lung cancer. Studies with a strong translational or clinical component that have the potential to evolve into, or be incorporated into, a full SPORE project and projects with multi-disciplinary collaborations and/or community-based participatory research studies are encouraged.

We encourage to submit your letter of intent (LOI) to anna.arnal@yale.edu

There is no deadline to apply, LOIs will be reviewed and eligible applicants will be invited to submit a full application online

at: <https://yale.infoready4.com/>

Read More

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

[Unsubscribe renee.gaudette@yale.edu](mailto:renee.gaudette@yale.edu)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by renee.gaudette@yale.edu powered by



Try email marketing for free today!

